FDA Pharmaceutical Companies Webinar 
Pharma Marketing Network
MARCH 19, 2025
Unlike traditional consumer brands, pharmaceutical companies face unique challenges on social media, including strict regulations, compliance concerns, and the need for factual accuracy. For pharmaceutical companies, this can provide insights into public perception of drug launches, patient experiences, and industry discussions.
Pharma Marketing Network
MARCH 18, 2025
Brand Authority: By appearing at the top of search engine results, pharmaceutical companies increase brand credibility among HCPs. Conversion Rate: Tracks how many users complete a desired action, such as signing up for a webinar or downloading whitepapers. Offer incentives like exclusive research reports or webinar invites.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Marketing Network
NOVEMBER 24, 2024
Use medical conferences, webinars, and educational content to connect with HCPs authentically. Use relatable metaphors: Think of content as a bridge connecting pharma companies with patients and HCPs. Navigating Regulatory Compliance Pharmaceutical advertising operates under strict regulations. Building trust is vital.
Pharma Marketing Network
APRIL 4, 2025
On the patient side, pharmaceutical companies have launched ambassador and mentorship programs. Patient support platforms may include features that allow users to invite others to educational webinars or support communities. Every message, endorsement, or testimonial must meet FDA, FTC, and local privacy regulations.
Pharma Marketing Network
FEBRUARY 27, 2025
Blogs, whitepapers, webinars, and infographics can help position your brand as a trusted authority. Using FDA-approved messaging and ensuring transparent disclaimers are critical in avoiding regulatory issues. Brands must adhere to HIPAA, FDA, and GDPR guidelines when collecting and using patient data.
ISPE
MARCH 6, 2023
To meet these challenges, pharmaceutical companies are accelerating digital transformation and making manufacturing more responsive to changing market conditions while improving efficiency. Pharma/Biopharma companies prefer a single system across a global manufacturing network, which further exacerbates this challenge.
pharmaphorum
DECEMBER 21, 2021
However, despite the work still left to be done, there are now a growing number of treatments in the pipeline and 2020 proved to be a remarkable year for orphan drug approvals, with the US FDA approving more orphan designated treatments than non-orphan drugs.
Expert insights. Personalized for you.
52 
Let's personalize your content